448906504
16 Nov 2019
United States Statement from Sarah Yim M.D. acting director of the Office of Therapeutic Biologics and Biosimilars in the FDAs Center for Drug Evaluation and Research on FDAs continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product, United states
Severity: Notice
Message: Undefined variable: region
Filename: views/login_detail_view_new_V1.php
Line Number: 393
Procurement News
Click for more details
If you have forgotten your User ID or Password, then please contact the TendersInfo Customercare by Email on customercare@tendersinfo.com.